Yes, there is a plan and yes, to be sure, dilution is coming. The market maker has helped run this stock this week. This is how investment banking works. I believe CYTX will be a long term winner because, while not terribly sophisticated, their stem cell harvesting process and stem cell applications work. And CYTX has important patents... Mark this message.
The question is will they stop a CYTX delisting? I hope not but I've been on the wrong side of similar biotech plays before (like Guilford Pharmaceuticals with one of the largest patent estates in biotech at the time). Management and debt holders have more to gain going that route and shaking off shareholders. I think CYTX technology has already been validated.
I've had just such a biotech delisting happen before (Guilford Pharmaceuticals). Shakes off all shareholders. All the IP and contracts fall to debt holders and management (viz. Symphony Partners in GLFD's case). I'm sure Lorem Vascular will be taken care of. I think that's management's plan.